The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by (89)Zr-immuno-PET in xenograft bearing mice

Probody(®) therapeutics are recombinant masked monoclonal antibody (mAb) prodrugs that become activated by proteases present in the tumor microenvironment. This makes them attractive for use as Probody drug conjugates (PDCs). CX-2009 is a novel PDC with the toxic drug DM4 coupled to an anti-CD166 Pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chomet, Marion, Schreurs, Maxime, Nguyen, Margaret, Howng, Bruce, Villanueva, Ruth, Krimm, Michael, Vasiljeva, Olga, van Dongen, Guus A.M.S, Vugts, Danielle J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255005/
https://www.ncbi.nlm.nih.gov/pubmed/32483421
http://dx.doi.org/10.7150/thno.44334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255005/
https://www.ncbi.nlm.nih.gov/pubmed/32483421
http://dx.doi.org/10.7150/thno.44334

Ejemplares similares